Medicines and Healthcare Products Regulatory Agency

Iqbal Mohamed Excerpts

Thursday 16th January 2025 Commons Chamber

[Iqbal Mohamed (Dewsbury and Batley) (Ind)]

Before being elected to this House I worked for nearly 20 years in the pharmaceutical regulation and compliance industry. I know from first-hand experience the critical role that the MHRA must play in protecting the public and its indispensable role in ensuring public trust in the medical sector. My comments, therefore, come from a place of wanting to ensure that that trust, so painstakingly built up, continues to be strengthened.

A recent survey by the Association of the British Pharmaceutical Industry found that 80% of respondents felt the MHRA’s lack of capacity was undermining industry trust and deterring domestic investment—problems compounded by Brexit, which has created obstacles to co-operation in the European Union. Faced with a large backlog of clinical trial applications, one would imagine the obvious solution is to make more resources available to recruit and train new staff, and to rebuild relationships with our European partners. However, the Prime Minister seems more determined to demonstrate his commitment to slashing red tape and the need to, as he says, “regulate smartly and regulate creatively”. I must admit I get very nervous when I hear that kind of language used in relation to the pharmaceutical industry, because it is normally code for measures that threaten safety standards even further.

The need for openness, transparency and regulation is probably greater than ever before. Recently, I have had constituents raise with me why the animal feed additive Bovaer, which is given to cows to reduce methane, is not tested or approved to MHRA pharmaceutical standards and why it is not even listed on milk cartons. Constituents have raised concerns with me about the use of carcinogenic chemicals in our food. We know that a host of chemicals that are banned from being used in food in the European Union are permitted in the United States. It is perfectly understandable for people to fear that, amid the bonfire of red tape that the Government are planning to set alight, some things that better protect us might go up in smoke.

Constituents have also raised questions with me about the latest impact of the covid-19 vaccines. Before anyone starts accusing me of being an anti-vaxxer, I took both covid vaccines and agree that they saved many lives, but it is also the case that legitimate concerns have been voiced about long-term side effects. We now know that in the largest vaccine study to date, two very rare side effects—a neurological disorder and inflammation of the spinal cord—have been detected. Other studies have confirmed side effects including inflammation of the heart muscle and the lining around the heart, particularly in young males, as well as blood clots in the brain’s venous sinuses.

Today we stand united in our commitment to safeguarding the health and wellbeing of our citizens. The motion highlights critical issues within the MHRA that demand our immediate attention and action. The Independent Medicines and Medical Devices Safety Review has shed light on persistent and exacerbated patient safety concerns since its publication in 2020, and it is our duty to ensure that the MHRA undergoes substantial revision to address those issues. The safety of our citizens must be paramount, and we cannot afford to overlook the shortcomings that have been identified.

In conclusion, let us not forget that our primary responsibility is to the people we serve. We must act with urgency and determination to rectify those issues with the MHRA. By implementing these recommendations, we can work towards a safer, more responsive healthcare system that prioritises patient safety and trust above corporate profits and interests